Clinical Trials on Ovarian Epithelial Carcinoma

Total 30497 results

University of Glasgow

Completed

Carboplatin Plus Paclitaxel or Docetaxel in Treating Patients With Ovarian Epithelial Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United Kingdom
University of Chicago
National Cancer Institute (NCI)

Withdrawn

FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer

Ovarian Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Ovarian Epithelial Cancer (ETC)

Ovarian Cancer

United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

Ovarian Neoplasms

United Kingdom, United States
Tesaro, Inc.
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Active, not recruiting

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST)

Ovarian Neoplasms | Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma

United States, Netherlands, Spain, Finland, Italy, Poland, Belgium, Canada, France, Germany, Romania, Ukraine, Norway, United Kingdom, Israel, Greece, Denmark, Belarus, Czechia
Pfizer

Terminated

Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer

Ovarian Neoplasms | Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Ovarian Carcinoma | Primary Peritoneal Carcinoma

United States
National Cancer Centre, Singapore

Terminated

Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-01)

Epithelial Ovarian Cancer

Singapore
National University Hospital, Singapore

Unknown

Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE)

Colorectal Cancer | Epithelial Ovarian Cancer | HNSCC | Organoids

Singapore
AbbVie

Withdrawn

A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer

Cancer - Ovarian
AstraZeneca
KuDOS Pharmaceuticals Limited

Completed

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer (ICEBERG 2)

Ovarian Neoplasm

United States, Spain, Australia, Germany, Sweden
Sohag University

Recruiting

Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Epithelial Ovarian Carcinoma

Ovarian Carcinoma

Egypt
Washington University School of Medicine
Aravive, Inc.

Withdrawn

Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma
National Cancer Institute (NCI)
NRG Oncology

Completed

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma

United States
Lei Li

Unknown

Cell-free DNA Methylation for Epithelial Ovarian Cancer

Epithelial Ovarian Cancer | Liquid Biopsy | DNA Methylation | Benign Ovarian Tumor | Training Set | Validation Set | Cell-free DNA

China
Affiliated Cancer Hospital & Institute of Guangzhou...
Chongqing University Cancer Hospital; Xiangya Hospital of Central South University and other collaborators

Recruiting

Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery (EHTASEOCCS)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

China
Shu-Zhong Cui
Xiangya Hospital of Central South University; Wuhan University; Peking University... and other collaborators

Unknown

Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer (EHNPCTASEOC)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal Carcinoma

China
Peking University People's Hospital
Beijing Weixiao Biotechnology Development Limited

Recruiting

Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer

Recurrent Ovarian Carcinoma | Platinum-resistant Ovarian Cancer

China
NovoCure Ltd.

Unknown

Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)

Ovarian Carcinoma

Switzerland, Belgium, Germany, Spain
HaEmek Medical Center, Israel

Terminated

Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy

Ovarian Carcinoma

Israel
Hospices Civils de Lyon

Unknown

Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer (HIPOVA-01)

Ovarian Epithelial Cancer

France
National Cancer Institute (NCI)

Completed

A Pilot Study of a Protein Profile Test in Ovarian Cancer Patients in Remission to See if Protein Changes Can Predict Relapse (be Predictive of Cancer Relapse)

Ovarian Neoplasm

United States
National Cancer Institute (NCI)

Completed

A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer

Ovarian Neoplasm

United States
University of California, Davis
National Cancer Institute (NCI); Amino Up Chemicals Co., Ltd.

Recruiting

Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy

Fallopian Tube Carcinoma | Peritoneal Carcinoma | Ovarian Epithelial Carcinoma

United States
Gdynia Oncology Center

Suspended

Preoperative Ascites Drainage Versus Standard Care for Patients With Advanced Ovarian Cancer

Malnutrition | Ovarian Epithelial Cancer | Ascites

Poland
TetraLogic Pharmaceuticals

Completed

Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer

Relapsed Epithelial Ovarian Cancer | Relapsed Primary Peritoneal Cancer | Relapsed Fallopian Tube Cancer

United States
Catholic University of the Sacred Heart

Completed

IPHC in Patients With Platinum-sensitive Recurrent Ovarian Cancer (IPHC)

Ovarian Epithelial Cancer Recurrent
Royal Surrey County Hospital NHS Foundation Trust

Unknown

Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival (MIRRORS)

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer | Ovarian Neoplasm | Ovarian Neoplasm Epithelial

United Kingdom
National Cancer Institute, Naples

Recruiting

Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer (MITO 22)

Low-grade Serous Ovarian Carcinoma | Recurrent Invasive Borderline Serous Ovarian Cancer

Italy
Sutro Biopharma, Inc.

Recruiting

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Ovarian Carcinoma | Ovary Cancer | Primary Peritoneal Carcinoma

United States
Mercy Medical Center

Active, not recruiting

HOT: HIPEC in Ovarian Cancer as Initial Treatment (CRS/HIPEC)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

Recurrent Ovarian Carcinoma | Ovarian Clear Cell Adenocarcinoma

United States, Korea, Republic of
Dana-Farber Cancer Institute
Celula, Inc.

Terminated

Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis

Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
Burzynski Research Institute

Terminated

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer

Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer
Lei Li

Unknown

A Training Set for the HRD Model in EOC

Epithelial Ovarian Cancer | Homologous Recombination Deficiency | Prognosis | BRCA Mutation | Loss of Heterozygosity | Platinum Resistance

China
Lei Li

Unknown

Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer

Epithelial Ovarian Cancer | BRCA1 Mutation | BRCA2 Mutation | Homologous Recombination Deficiency | Prognosis | Chinese

China
Assistance Publique - Hôpitaux de Paris

Completed

Microscopic Peritoneal Metastases After Complete Macroscopic Cytoreductive Surgery for Epithelial Ovarian Cancer (MicroPCI)

Epithelial Ovarian Cancer

France
JSehouli

Completed

Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer

Recurrent Epithelial Ovarian Cancer

Germany
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States, Canada
Memorial Sloan Kettering Cancer Center
Queens Cancer Center of Queens Hospital

Completed

Women Surviving Ovarian Cancer

Quality of Life | Epithelial Ovarian Cancer | Survivorship

United States
NYU Langone Health
GlaxoSmithKline

Withdrawn

Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of Progression

Ovarian Carcinoma

United States
National Taiwan University Hospital

Unknown

IGFBP-3 in Ovarian Cancer Invasion

Ovarian Carcinoma

Taiwan
Grupo Español de Investigación en Cáncer de Ovario
Roche Pharma AG

Terminated

Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin (NOVA)

Cancer, Ovarian

Spain
Imperial College London
GlaxoSmithKline

Completed

[18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer (PAZPET-1)

Ovarian Neoplasm

United Kingdom
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Stage IV Ovarian Cancer | Stage III Ovarian Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian... and other conditions

United States
Lei Li

Recruiting

Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer

Recurrent Ovarian Carcinoma | Platinum-resistant Ovarian Cancer | Bevacizumab | Ovarian Carcinoma | Survival Outcomes | Adverse Events | Albumin-bound Paclitaxel

China
Shanghai Gynecologic Oncology Group
Fudan University; Shanghai Zhongshan Hospital; Shanghai Jiao Tong University...

Completed

First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer (AICE)

Fallopian Tube Cancer | Primary Peritoneal Carcinoma | Bulky Stage IIIC and IV Epithelial Ovarian Cancer

China
Allarity Therapeutics
Amarex Clinical Research; Alcedis GmbH

Recruiting

Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® (PREDICT 2X-121)

Advanced Ovarian Cancer

United Kingdom, United States
Grupo Español de Investigación en Cáncer de Ovario
AstraZeneca

Completed

Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin (ROLANDO)

Advanced Ovarian Cancer

Spain

Clinical Trials on Ovarian Epithelial Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations